Product details

Share this page:
Please find below the full details of the product you clicked a link to view.
Reference no. 9-210-040
Prize winner
Published by:
Harvard Business Publishing (2011)
28 September 2011
32 pages
Data source:
Field research
Franz Humer, CEO of the Roche Group, must decide whether to mount a hostile tender offer for the publicly-owned shares of Roche's biotechnology subsidiary, Genentech. The case provides opportunities to analyze Roche's strategy with respect to Genentech, the pros and cons of merging the two companies with different cultures, the value of Genentech, and the tactics of a hostile tender offer. This case has been featured on our website, click to view the article.
Switzerland, Biotechnology; Pharmaceuticals, 2008-2009, USD43 billion revenue, 78,000 employees
Prizes won:
View our pricing guide
or to see prices.